28 results found

Borgernes frie valg af leverandør bliver ofte begrænset af kommuner og regioner, når de udbyder ernæringspræparater, som en ikke udbudspligtig opgave og hverken...

Recent U.S. case law is reshaping the risks around skinny labelling strategies for generics. What was once seen as a safe regulatory pathway now raises new concerns about infringement

The EU Court of Justice faces a pivotal decision on whether medicines approved as monotherapy but labeled for use in combination with other drugs qualify for Supplementary Protection Certificate (SPC) protection as combinations of active ingredients. This referral, stemming from Genmab's attempts to secure SPC protection for loose combinations including daratumumab, could resolve over a decade of legal uncertainty and fundamentally reshape how pharmaceutical companies approach regulatory strategy for combin

Welcome to this edition of Kromann Reumert's Life Science Update. In the following, we provide an overview of recent legal updates that will have a bearing on the life science industry across Europe...

With the current Danish life science strategy set to expire by the end of 2023, the Danish Government requested the Danish Life Science Council to provide recommendations...